NextConsensus
Start with one claim

The record for one asset, dated and chained

A team with a submission date, a coverage review, or a transaction closing gets the record about its asset as it stands: every act the deciding institutions have recorded, each dated to the day its source carries, tied to an archived copy by its digest, and chained so an edit anywhere shows.

These published ledgers show what an evaluation delivers for an asset. Nothing on a ledger is estimated; the registered record an asset may also have lives on its own page and is linked, not restated.

Start with one claim Read the full ledger

Sunvozertinib, first line, EGFR exon 20 insertion NSCLC

2026-05-27 → 2026-08-17 · 8 rows · record hash chain d668f1a1d4d1…

First-line use of sunvozertinib in EGFR exon 20 insertion mutation-positive NSCLC: the trial readout, its publication, regulatory filings and designations, and the guideline position, each as the institution or its recorder stated it.

Date Institution What was recorded Source Digest
China NMPA, Center for Drug Evaluation — as recorded by the sponsor Dizal release: the CDE “has accepted and granted priority review to the New Drug Application (NDA) for ZEGFROVY® (sunvozertinib)” in EGFR exon 20 insertion mutation-positive NSCLC, headlined as first-line treatment and “based on the results of WU-KONG28 study”. SRC-004 retrieved 2026-07-31 sha256 6dc5663822dd9950c749c765045abe4c3ce4d8f6f632251106d222c577549214 chain 4608f395d1668ed46c9541b81e4f8f629f99b3190477c4906c0782d686c7d650
Dizal (sponsor) Dizal announces WU-KONG28 phase 3 results. The release headlines that sunvozertinib “outperforms platinum-doublet chemotherapy” in first-line EGFR exon 20 insertion mutation-positive NSCLC, “presented as a Late-Breaking Abstract Oral Presentation (#LBA8500)” at ASCO 2026 “and simultaneously published in The New England Journal of Medicine”. SRC-001 retrieved 2026-07-31 sha256 8d36a5ba14efa04cbdbbc0ea3ceda931828048f5dfdeed0c9621ed5fdd394489 chain 49a03be772ed184d1a6834b43f5414a86dbe30a91ef277ee72c2d60e3e8ab323
The New England Journal of Medicine — PubMed record Primary publication indexed: “First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations”, N Engl J Med, PMID 42212913, doi 10.1056/NEJMoa2604461. Archived as the PubMed record because the publisher served a bot-challenge page rather than the article. SRC-002 retrieved 2026-07-31 sha256 a8b05e1e6f2c03013cad238c9404d0f10d28437e26d60251c01d55052a61a6fe chain 0ee99e5f59acb815f375816bb7c28bfd0149b16afcfeb06434a7a185dcdcc94c

All 8 rows, the chain scheme, and the steps to recompute it

Observation only: dated, sourced, and hash-chained. Phase 0, 2026-09-06.

A ledger is a snapshot. When a guideline body, a regulator, or a payer next acts on the asset a ledger covers, the action is dated and sourced on the evidence change feed.